JPWO2022188856A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022188856A5 JPWO2022188856A5 JP2023555769A JP2023555769A JPWO2022188856A5 JP WO2022188856 A5 JPWO2022188856 A5 JP WO2022188856A5 JP 2023555769 A JP2023555769 A JP 2023555769A JP 2023555769 A JP2023555769 A JP 2023555769A JP WO2022188856 A5 JPWO2022188856 A5 JP WO2022188856A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/080142 | 2021-03-11 | ||
| CN2021080142 | 2021-03-11 | ||
| CNPCT/CN2022/076516 | 2022-02-16 | ||
| CN2022076516 | 2022-02-16 | ||
| PCT/CN2022/080297 WO2022188856A1 (en) | 2021-03-11 | 2022-03-11 | Method of treating diseases using gremlin1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513692A JP2024513692A (ja) | 2024-03-27 |
| JP2024513692A5 JP2024513692A5 (https=) | 2025-03-19 |
| JPWO2022188856A5 true JPWO2022188856A5 (https=) | 2025-03-19 |
Family
ID=83226314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555769A Pending JP2024513692A (ja) | 2021-03-11 | 2022-03-11 | グレムリン１アンタゴニストを使用して疾患を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240190950A1 (https=) |
| EP (1) | EP4304646A4 (https=) |
| JP (1) | JP2024513692A (https=) |
| KR (1) | KR20230156936A (https=) |
| CN (1) | CN116940380A (https=) |
| AU (1) | AU2022233762A1 (https=) |
| BR (1) | BR112023018204A2 (https=) |
| CA (1) | CA3213121A1 (https=) |
| MX (1) | MX2023010594A (https=) |
| TW (1) | TW202300527A (https=) |
| WO (1) | WO2022188856A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
| CN119746060B (zh) * | 2025-03-07 | 2025-09-16 | 南昌大学第一附属医院 | 一种树突状细胞疫苗制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| ES2898620T3 (es) * | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Anticuerpos humanos contra GREM 1 |
| US10844051B2 (en) * | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| PL3806898T3 (pl) * | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
-
2022
- 2022-03-11 BR BR112023018204A patent/BR112023018204A2/pt unknown
- 2022-03-11 MX MX2023010594A patent/MX2023010594A/es unknown
- 2022-03-11 CN CN202280020454.8A patent/CN116940380A/zh active Pending
- 2022-03-11 KR KR1020237034659A patent/KR20230156936A/ko active Pending
- 2022-03-11 WO PCT/CN2022/080297 patent/WO2022188856A1/en not_active Ceased
- 2022-03-11 EP EP22766378.8A patent/EP4304646A4/en active Pending
- 2022-03-11 TW TW111109016A patent/TW202300527A/zh unknown
- 2022-03-11 JP JP2023555769A patent/JP2024513692A/ja active Pending
- 2022-03-11 CA CA3213121A patent/CA3213121A1/en active Pending
- 2022-03-11 AU AU2022233762A patent/AU2022233762A1/en active Pending
- 2022-03-11 US US18/549,928 patent/US20240190950A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI725037B (zh) | 抗體-藥物結合物之選擇的製造方法、抗體-藥物結合物組成物及醫藥組成物 | |
| US7498142B2 (en) | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies | |
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| CN103189392B (zh) | ErbB3结合抗体 | |
| CA3089653A1 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| JP2010518820A5 (https=) | ||
| US20210261676A1 (en) | Anti-Baff Receptor Antibodies and Uses Thereof | |
| JP2022526841A5 (https=) | ||
| CN116940380A (zh) | 使用grem1拮抗剂治疗疾病的方法 | |
| WO2019114793A1 (zh) | 一种egfr抗体及其制备方法和应用 | |
| JPWO2022188856A5 (https=) | ||
| JPWO2020210067A5 (https=) | ||
| JPWO2022152290A5 (https=) | ||
| JP7753401B2 (ja) | ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| JPWO2022159984A5 (https=) | ||
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| WO2024030341A1 (en) | Compositions for targeted lysosomal degradaton and methods of use thereof | |
| US9464136B2 (en) | Antibody-based constructs directed against tyrosine kinase receptors | |
| JPWO2020210247A5 (https=) | ||
| JPWO2022217019A5 (https=) | ||
| RU2018111298A (ru) | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека | |
| TW202540198A (zh) | 雙特異性抗體樣蛋白以及彼之製造及使用方法 | |
| RU2025134255A (ru) | Конъюгат антитела к рецептору эпидермального фактора роста (egfr) и лекарственного средства и его применение |